Genzyme May Initiate More Clolar Trials In 2005
56545
Piper Jaffray maintained an &quot;outperform&quot; rating and $70 target price on Genzyme (nasdaq: GENZ - news - people ), citing the FDA&#39;s approval of Clolar for the treatment of pediatric acute lymphocytic leukemia (ALL) in patients between 1 and 21 years who
756888
Scientists launched a trial on Monday to test whether a new drug works as an initial treatment against the most common form of lung cancer.
555792
A panel of medical experts on Wednesday said Ilex Oncology Inc.&#39;s new drug Clolar was &quot;reasonably likely&quot; to help children and young adults with a cancer called acute lymphocytic leukemia.
598449
NEW YORK  - An enzyme has been recently identified that is able to degrade gluten in a laboratory simulation of the gastrointestinal tract.
388102
Pre-clinical trial results are mixed, but mark a major step forward for developing human treatments.
572919
Biotech titan Genzyme (Nasdaq: GENZ) has its roots in the treatment of rare genetic diseases and also has a significant presence in the treatment of renal diseases and providing diagnostic testing services.
378174
Medical researchers have obtained promising results from a trial of a genetically-engineered allergy vaccine.
626896
Mixing cells and eggs to be allowed in search for new medical treatments.
586388
A gene therapy trial starts which scientists hope will extend the lives of patients with muscular dystrophy.
667689
The biotech firm advances to next stage of clinical studies in stem cell research.
536259
Genzyme Corp.'s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug Administration recommended the agency approve Ilex's experimental cancer treatment for children with certain types of leukemia.
99180
THE REGION Cambridge biotech company Dyax Corp. has agreed to end its deal with Genzyme Corp. to codevelop a drug for the rare swelling disorder hereditary angioedema. The firms were jointly testing DX-88, a small protein considered Dyax's most important potential drug. Dyax said it will receive all the assets of the joint development deal and $17 million cash. Genzyme ...
654609
Genzyme and Millenium vie to purchase the Canadian biotech.
129803
Blocking a specific enzyme may be enough to check the spread of cancer in the body, researchers believe.
560148
The Food and Drug Administration approved Clolar, Genzyme Corp.&#39;s new drug for patients under 21 with acute lymphocytic leukemia.
147168
The approval of a new drug is a long-term opportunity.
494130
Genzyme Corp. announced Wednesday that its drug Clolar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with difficult or relapsed acute lymphoblastic leukemia (ALL).